CN101180297A - 作为hsp90-抑制剂的炔基吡咯并嘧啶及相关类似物 - Google Patents

作为hsp90-抑制剂的炔基吡咯并嘧啶及相关类似物 Download PDF

Info

Publication number
CN101180297A
CN101180297A CNA2006800175550A CN200680017555A CN101180297A CN 101180297 A CN101180297 A CN 101180297A CN A2006800175550 A CNA2006800175550 A CN A2006800175550A CN 200680017555 A CN200680017555 A CN 200680017555A CN 101180297 A CN101180297 A CN 101180297A
Authority
CN
China
Prior art keywords
base
compound
dimethyl
enantiomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800175550A
Other languages
English (en)
Chinese (zh)
Inventor
S·R·卡西布阿特拉
M·A·比阿蒙特
史建栋
M·F·贝姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conforma Therapeutics Corp
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37054161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101180297(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of CN101180297A publication Critical patent/CN101180297A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
CNA2006800175550A 2005-03-30 2006-03-29 作为hsp90-抑制剂的炔基吡咯并嘧啶及相关类似物 Pending CN101180297A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66689905P 2005-03-30 2005-03-30
US60/666,899 2005-03-30

Publications (1)

Publication Number Publication Date
CN101180297A true CN101180297A (zh) 2008-05-14

Family

ID=37054161

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800175550A Pending CN101180297A (zh) 2005-03-30 2006-03-29 作为hsp90-抑制剂的炔基吡咯并嘧啶及相关类似物

Country Status (15)

Country Link
US (2) US7544672B2 (US07544672-20090609-C00215.png)
EP (1) EP1869027A4 (US07544672-20090609-C00215.png)
JP (1) JP2008534609A (US07544672-20090609-C00215.png)
KR (1) KR20080004550A (US07544672-20090609-C00215.png)
CN (1) CN101180297A (US07544672-20090609-C00215.png)
AU (1) AU2006230447A1 (US07544672-20090609-C00215.png)
BR (1) BRPI0609509A2 (US07544672-20090609-C00215.png)
CA (1) CA2602257A1 (US07544672-20090609-C00215.png)
EA (1) EA013522B1 (US07544672-20090609-C00215.png)
IL (1) IL186270A (US07544672-20090609-C00215.png)
MX (1) MX2007011903A (US07544672-20090609-C00215.png)
NO (1) NO20075099L (US07544672-20090609-C00215.png)
NZ (1) NZ561939A (US07544672-20090609-C00215.png)
WO (1) WO2006105372A2 (US07544672-20090609-C00215.png)
ZA (1) ZA200708520B (US07544672-20090609-C00215.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192712A (zh) * 2022-07-05 2022-10-18 四川大学华西第二医院 Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544672B2 (en) * 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
WO2007104944A1 (en) * 2006-03-11 2007-09-20 Vernalis (R & D) Ltd. Pyrrolopyrimidine derivatives used as hsp90 inhibitors
US20070259820A1 (en) * 2006-05-03 2007-11-08 The Regents Of The University Of Michigan Methods and reagents for activating heat shock protein 70
EP2038041A4 (en) 2006-05-12 2010-02-17 Myriad Genetics Inc THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
WO2008045529A1 (en) * 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
ATE487720T1 (de) 2007-02-01 2010-11-15 Astrazeneca Ab 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EP2118111B1 (en) * 2007-02-06 2011-03-23 Pfizer Inc. 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer
WO2009030871A1 (en) * 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
CA2732922A1 (en) 2008-08-13 2010-02-18 Pfizer Inc. 2-amino pyrimidine compounds as potent hsp-90 inhibitors
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
GB0819105D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
GB0819102D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US8633322B2 (en) * 2009-10-29 2014-01-21 Janssen Pharmaceutica Nv Alkynyl derivatives useful as DPP-1 inhibitors
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
WO2015153496A1 (en) * 2014-03-30 2015-10-08 Cepheid Modified thymine polynucleotide oligomers and methods
CN106460058B (zh) * 2014-03-30 2019-07-09 赛沛 经修饰的胞嘧啶多核苷酸寡聚物和方法
KR102133569B1 (ko) * 2018-06-28 2020-07-13 한국과학기술연구원 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3595955A (en) * 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US4533254A (en) * 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4806642A (en) * 1984-10-05 1989-02-21 Warner-Lambert Company Purine derivatives
US5098906A (en) * 1983-10-31 1992-03-24 Warner-Lambert Company Purine derivatives
US4921859A (en) * 1983-10-31 1990-05-01 Warner-Lambert Company Purine derivatives
US4547573A (en) * 1983-12-02 1985-10-15 Ici Pharma Process for preparing cephalosporin derivatives
EP0151528B1 (en) 1984-02-02 1990-07-04 Merck & Co. Inc. 5-(amino or substituted amino)-1,2,3-triazoles
US4748177A (en) * 1984-03-26 1988-05-31 Warner-Lambert Company Guanine derivatives
US4617304A (en) * 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
IT1196261B (it) * 1984-09-20 1988-11-16 Pierrel Spa Derivati nucleosidici e purinici 8-sostituiti
IL76546A (en) 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
US4772606A (en) * 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
JO1406B1 (en) 1984-11-02 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Chemical compounds
US5217866A (en) * 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
WO1986005518A1 (en) 1985-03-15 1986-09-25 James Summerton Stereoregular polynucleotide-binding polymers
DE3512194A1 (de) * 1985-04-03 1986-10-09 Hoechst Ag, 6230 Frankfurt Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US4918162A (en) * 1986-05-06 1990-04-17 The Regents Of The University Of California Assays and antibodies for N-MYC proteins
US5002950A (en) * 1986-10-24 1991-03-26 Warner-Lambert Co. 7-deazaguanines as immunomodulators
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5204353A (en) * 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
SE8801729D0 (sv) 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
US4923885A (en) * 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
EP0363320A3 (de) * 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
DE69116750T2 (de) 1990-07-04 1996-11-14 Merrell Dow Pharma 9-Purinyl-Phosphonsäurederivate
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
EP0502690B1 (en) 1991-03-05 1999-12-01 Ajinomoto Co., Inc. Cyclopropane derivative
WO1992021032A1 (en) * 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) * 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
HU9401936D0 (en) 1992-01-06 1994-09-28 Pfizer Process and uses for 4,5-diohydrogeldanamycin and its hydroquinone
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
JPH0680670A (ja) 1992-09-03 1994-03-22 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6444656B1 (en) * 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5744492A (en) 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
JP3769737B2 (ja) 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH0841035A (ja) 1994-08-05 1996-02-13 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US5846749A (en) * 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
JPH08208687A (ja) 1994-11-25 1996-08-13 Sankyo Co Ltd グリセリルオリゴヌクレオチド
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
JPH0920776A (ja) 1995-06-30 1997-01-21 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする抗ウイルス剤
JPH09169758A (ja) 1995-10-18 1997-06-30 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法、及びそれを用いた抗ウイルス剤
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
US6028076A (en) 1996-07-03 2000-02-22 Japan Energy Corporation Purine derivative
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US5861503A (en) * 1997-04-30 1999-01-19 The Regents Of The University Of California Process for producing 8-fluoropurines
JP4903922B2 (ja) 1997-05-14 2012-03-28 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 選択された蛋白質を分解する複合化合物
WO1999001454A1 (en) * 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
WO1999002162A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
AU4656997A (en) 1997-09-30 1999-04-23 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
JP2000072773A (ja) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd プリン誘導体
JP2000072733A (ja) 1998-08-31 2000-03-07 Kanebo Ltd アミド化合物の製造法
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6369092B1 (en) * 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
JP2002532535A (ja) 1998-12-22 2002-10-02 アメリカ合衆国 水不溶性薬剤送達システム
PT1149111E (pt) * 1999-01-06 2009-11-19 Univ Southern California Processo e composição para a inibição da angiogénese
RU2001124352A (ru) 1999-02-01 2004-02-20 Си Ви Терапьютикс, Инк. (Us) Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа
FR2790702B1 (fr) 1999-03-08 2001-07-20 Sidel Sa Unite de moulage et machine d'extrusion-soufflage munie d'une telle unite
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
JP2002541255A (ja) 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN101928288B (zh) * 2000-11-02 2013-09-11 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
US20020156277A1 (en) * 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US20030022864A1 (en) * 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
US6962991B2 (en) * 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
JP2003113181A (ja) 2001-10-04 2003-04-18 Sumika Fine Chemicals Co Ltd ６−ハロプリンの製造方法
AU2002343604C1 (en) * 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
ATE449099T1 (de) 2002-08-08 2009-12-15 Memory Pharm Corp Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
WO2004024082A2 (en) 2002-09-13 2004-03-25 Irm, Llc Highly specific modulators of gtpases for target validation
EP1546164A4 (en) 2002-09-26 2006-06-07 Lg Life Sciences Ltd (+) - TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION OF STEREO-ISOMERS THEREOF, AND THE USE OF ANTIVIRAL AGENTS PRODUCED THEREOF
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
NZ544988A (en) 2003-07-30 2009-11-27 Gilead Sciences Inc Nucleobase phosphonate analogs for antiviral treatment
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
EA009920B1 (ru) * 2003-08-29 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения пиримидотиофена
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
CN100475815C (zh) 2003-09-25 2009-04-08 詹森药业有限公司 抑制hiv复制的嘌呤衍生物
KR20050062940A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
KR20050062944A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-클로로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
TW200533358A (en) 2004-02-17 2005-10-16 Anadys Pharmaceuticals Inc Nucleoside phosphonate derivatives useful in the treatment of hiv infections
WO2005092892A1 (ja) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ８−オキソアデニン化合物
US7544672B2 (en) * 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192712A (zh) * 2022-07-05 2022-10-18 四川大学华西第二医院 Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用
CN115192712B (zh) * 2022-07-05 2023-08-01 四川大学华西第二医院 Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用

Also Published As

Publication number Publication date
BRPI0609509A2 (pt) 2010-04-13
IL186270A (en) 2012-08-30
MX2007011903A (es) 2007-12-05
WO2006105372A2 (en) 2006-10-05
IL186270A0 (en) 2008-01-20
US7544672B2 (en) 2009-06-09
JP2008534609A (ja) 2008-08-28
US8093229B2 (en) 2012-01-10
EA013522B1 (ru) 2010-06-30
EP1869027A4 (en) 2010-06-23
WO2006105372A3 (en) 2007-07-19
CA2602257A1 (en) 2006-10-05
NO20075099L (no) 2007-10-29
US20090318387A1 (en) 2009-12-24
ZA200708520B (en) 2008-10-29
KR20080004550A (ko) 2008-01-09
EP1869027A2 (en) 2007-12-26
EA200702109A1 (ru) 2008-06-30
AU2006230447A1 (en) 2006-10-05
US20060223797A1 (en) 2006-10-05
NZ561939A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
CN101180297A (zh) 作为hsp90-抑制剂的炔基吡咯并嘧啶及相关类似物
KR101156845B1 (ko) 헤테로시클릭 키나제 조절제
EP2958923A1 (de) 4-substituierte pyrrolo- und pyrazolo-diazepine
TW201444833A (zh) 經胺基取代之異噻唑類
JP2016513117A (ja) 過剰増殖性疾患を治療するためのｂｅｔタンパク質阻害剤としてのピロロ−およびピラゾロ−トリアゾロジアゼピン類
JP2012507569A (ja) ピラゾロピリミジンｊａｋ阻害剤化合物と方法
JP4976394B2 (ja) 新規な高親和性のキノリンベースのキナーゼリガンド
CN101679387A (zh) 可用作激酶抑制剂的氨基嘧啶类化合物
CN101801959A (zh) 可用作激酶抑制剂的氨基嘧啶类化合物
JP2009504756A (ja) 新規な高親和性のチオフェンベースおよびフランベースのキナーゼリガンド
TW202317198A (zh) Ｋｒａｓ抑制劑結合物
CN101679386A (zh) 可用作激酶抑制剂的氨基嘧啶类化合物
WO2013174743A1 (en) Substituted pyrrolopyrimidines
CN101160316A (zh) 适合用作aurora激酶抑制剂的噻吩并嘧啶
CN102083831A (zh) 用作aurora激酶抑制剂的萘啶酮
JP2024516317A (ja) Ｓｈｐ２リン酸化酵素阻害剤の調製と応用
AU2013326408A1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080514